key: cord-0822254-jpskca7w
authors: Menez, Steven; Moledina, Dennis G.; Thiessen-Philbrook, Heather; Wilson, F. Perry; Obeid, Wassim; Simonov, Michael; Yamamoto, Yu; Corona-Villalobos, Celia P.; Chang, Crystal; Garibaldi, Brian T.; Clarke, William; Farhadian, Shelli; Dela Cruz, Charles; Coca, Steven G.; Parikh, Chirag R.
title: Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19
date: 2021-10-25
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2021.09.008
sha: 93dc49e15594eb443378e848bcb568c3753e253e
doc_id: 822254
cord_uid: jpskca7w

RATIONALE AND OBJECTIVE: Acute kidney injury (AKI) is common in patients with COVID-19 and associated with poor outcomes. Urinary biomarkers have been associated with adverse kidney outcomes in other settings and may provide additional prognostic information in patients with COVID-19. We investigated the association between urinary biomarkers with adverse kidney outcomes among patients hospitalized with COVID-19. STUDY DESIGN: Prospective cohort study. SETTING AND PARTICIPANTS: Patients hospitalized with COVID-19 (n=153) at 2 academic medical centers between April and June 2020. EXPOSURES: 19 urinary biomarkers of injury, inflammation, and repair. OUTCOMES: Composite of KDIGO stage 3 AKI, requirement for dialysis, or death within 60 days of hospital admission. We also compared various kidney biomarker levels in the setting of COVID-19 versus other common AKI settings. ANALYTIC APPROACH: Time-varying Cox proportional hazards regression to associate biomarker level with composite outcome. RESULTS: Out of 153 patients, 24 (15.7%) experienced the primary outcome. Two-fold higher levels of neutrophil gelatinase-associated lipocalin (NGAL) (HR: 1.34; 95% CI: 1.14-1.57), monocyte chemoattractant protein (MCP-1) (HR: 1.42; 95% CI: 1.09-1.84), and kidney injury molecule-1 (KIM-1) (HR: 2.03; 95% CI: 1.38-2.99) were associated with highest risk of sustaining primary composite outcome. Higher epidermal growth factor (EGF) levels were associated with a lower risk of the primary outcome (HR 0.61; 95% CI: 0.47-0.79). Individual biomarkers provided moderate discrimination and biomarker combinations improved discrimination for the primary outcome. The degree of kidney injury by biomarker level in COVID-19 was comparable to other settings of clinical AKI. There was evidence of subclinical AKI in COVID-19 patients based on elevated injury biomarker level in patients without clinical AKI defined by serum creatinine. LIMITATIONS: Small sample size with low number of composite outcome events. CONCLUSION: Urinary biomarkers are associated with adverse kidney outcomes in patients hospitalized with COVID-19 and may provide valuable information to monitor kidney disease progression and recovery.

As of August 2021, over 200 million people have been infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across 192 countries and territories 1, 2 . As many as 20-25% of patients admitted to the hospital with the novel Coronavirus Disease of 2019 require intensive care unit (ICU) admission, with in-hospital mortality between 5% and 20% 3, 4 . Clinical acute kidney injury (AKI), defined by serum creatinine KDIGO criteria, occurs in nearly 30-50% of hospitalized patients, among whom 19% require dialysis [5] [6] [7] [8] .

Furthermore, clinical AKI during hospital admission has been associated with greater need for ICU admission 9 , and worse in-hospital mortality 10 .

In a consensus report of the 25 th Acute Disease Quality Initiative Workgroup, Nadim et al. concluded that the pathogenesis of COVID-19-associated AKI is not yet fully elucidated and likely multifactorial 11 . Endothelial dysfunction, coagulopathy, complement activation, systemic inflammation, and immune dysfunction may all play a role in disease pathogenesis affecting the kidney 11 . Risk factors for the development of AKI in the setting of COVID-19 include black race, male sex, age over 50 years, diabetes mellitus, hypertension, obesity, and heart failure 9, 11 . We showed, however, that even after adjusting for such risk factors, patients with COVID-19 have a more than 40% higher risk of AKI compared with patients without COVID-19 7 . The mechanism for this higher AKI risk remains unexplained. The long-term impact of COVID-19 is also uncertain from both kidney-specific and more global standpoints, with growing concern for the disease's long-term physiological and psychological effects 12 .

Biomarkers of kidney injury, inflammation, and repair may offer further insight beyond current standard methods of characterizing COVID-19-associated AKI 13 . Biomarkers can help to differentiate various types of kidney injury 14, 15 , and may be uniquely helpful in quantifying J o u r n a l P r e -p r o o f tubular injury in COVID- 19 . In this study, therefore, we explored the association of urinary biomarkers of kidney injury, inflammation, and repair with severe AKI and death in patients hospitalized with COVID-19. We additionally evaluated biomarkers in patients with normal serum creatinine to identify the subset of patients with subclinical AKI, which has been consistently associated with adverse outcomes 16, 17 . To estimate the magnitude of tubular injury in COVID-19 and provide insight into pathogenesis, we compared biomarkers of injury, inflammation, and repair in the kidney across different AKI settings.

We hypothesized that several biomarkers across different biological pathways would be significantly elevated, and that higher levels would be associated with an increased risk of severe AKI, requirement for dialysis, and death. We also hypothesized that the degree of injury to the tubules in hospitalized patients with COVID-19-associated AKI would be more severe than in other hospitalized AKI settings given the general trend of severe critical illness requiring mechanical ventilation and maximum hemodynamic support seen in the first wave of the COVID-19 pandemic.

We obtained patient data and biosamples for the present study from 2 academic medical centers, the Johns Hopkins Hospital in Baltimore, Maryland, and Yale New Haven Hospital in New Haven, Connecticut, between April and June 2020 as part of the Translational Investigation of Kidney Disease in COVID-19 (TRIKIC) Consortium. Both health care systems used similar institutional protocols to prospectively collect data and biosamples in hospitalized adult inpatients with confirmed COVID-19 by PCR testing. Inpatients who did not have urine samples available for biomarker measurement before the onset of stage 3 AKI were excluded. Inpatients with baseline serum creatinine ≥ 4 mg/dL were also excluded. Baseline comorbidities were defined by mapping ICD-10 codes to the Elixhauser comorbidity index 19 . Laboratory values and vital signs on admission were defined as the first available values after admission.

Urine samples were collected after a patient's admission with a confirmed COVID-19 test, with repeat urine sample collections attempted weekly thereafter for patients who remained hospitalized. Samples were collected either after informed consent was obtained or as leftover residuals from clinical samples. Urine samples were collected at a median of 6 (IQR 2-10) days after hospital admission for all patients. For patients who experienced the primary outcome, samples were collected at a median of 9.5 days (IQR 4.5-17) after hospital admission and in patients who did not experience the primary outcome at a median of 5 days (IQR 2-9) days after hospital admission. Only urine samples collected before the time of the primary outcome were included in analysis. Details on sample processing and biomarker measurement can be found in the Item S1. Inter-assay and intra-assay coefficients of variability (CV) were evaluated for all measured biomarkers (Table S1). We selected 9 candidate urinary biomarkers as primary exposure variables based on our prior work demonstrating associations of such biomarkers with adverse short and long-term kidney outcomes in other clinical settings 14, [20] [21] [22] . These 9 urinary biomarkers were as follows: albumin; epidermal growth factor (EGF); kidney injury molecule-1 J o u r n a l P r e -p r o o f (KIM-1); monocyte chemoattractant protein-1 (MCP-1); neutrophil gelatinase-associated lipocalin (NGAL); osteopontin (OPN); uromodulin (UMOD); IL-18; and YKL-40. Given the marked systemic inflammatory response associated with COVID-19, we additionally investigated the association of 10 inflammatory biomarkers with the primary outcome: urinary IL-1β, 2, 4, 6, 8, 10, 12, and 13; tumor necrosis factor alpha (TNF-α); and interferon-γ (IFN-γ).

All biomarker measurements were obtained from all urine samples were used in our analyses.

Urine microscopy scoring was completed in a subset of 59 patients at the Johns Hopkins site, using the IDEXX SediVue Dx ® platform 23 , with all 59 urine microscopy samples generating an automated report with 70 images each, which were reviewed manually. All urine microscopy measurements were made on the same urine samples for which biomarkers were measured, in patients at the Johns Hopkins Hospital. The urine microscopy score was determined based on the number of renal tubular epithelial cells per high-power field, and number of granular casts per low-power field 24 . We use reverse-transcriptase polymerase chain reaction (RT-PCR) testing to evaluate for the presence of the SARS-CoV-2 virus in urine samples of 55 patients from the Johns Hopkins Hospital.

Baseline kidney function was defined using the median of all outpatient serum creatinine measurements 7 to 365 days before hospitalization, if available. This definition was chosen given the concern that serum creatinine values measured closest to the time of hospitalization in patients with COVID-19 may already be elevated above baseline. In the 17% of patients without any outpatient serum creatinine measurements available, the lowest serum creatinine value obtained during the COVID-19 hospitalization, was used as the baseline creatinine. In patients J o u r n a l P r e -p r o o f who were started on dialysis during hospitalization, we ensured that no serum creatinine values were used to calculate baseline kidney function after the start of dialysis. Otherwise, when needed we used the lowest value of serum creatinine at any point during hospitalization to determine baseline. Estimated glomerular filtration rates (eGFRs) were calculated using the Chronic Kidney Disease Epidemiology Collaboration equation 25 . Clinical AKI was defined as an increase ≥ 50% in serum creatinine from baseline or dialysis at any time during the index hospitalization. AKI severity was classified by modified Kidney Disease: Improving Global Outcomes (KDIGO) staging criteria on the basis of the peak serum creatinine during the index hospitalization 26 . Stage 3 AKI was defined as a 3-fold increase in serum creatinine, a peak serum creatinine value > 4 mg/dL with at least a 50% increase in serum creatinine, or dialysis at any time during the index hospitalization. If multiple serum creatinine measurements were available within the same day, the mean value for the day was used. The primary outcome of the study was the time to a composite of Stage 3 AKI, dialysis, or death within 60 days of hospital admission.

Descriptive characteristics were reported using mean ± standard deviation or median (interquartile range) for continuous variables, and frequency (percentage) for categorical variables. All biomarkers were modeled continuously after log2 transformation. Vital signs and clinical laboratory values were primarily obtained on the day of admission, with the exception of urinalysis (Table S2) .

Time-varying Cox proportional hazards regression was used to examine the association between urinary biomarker levels and the primary outcome using all available biomarker measurements prior to the development of the primary outcome, with time of each biomarker J o u r n a l P r e -p r o o f measurement taken into consideration. We performed all analyses after log2 transformation of biomarker measurements, first with univariable analysis, and then with indexing to the urine creatinine concentration in order to account for any influence that urinary dilution or concentration based on a patient's hydration status may have on biomarker level. We further adjusted for World Health Organization (WHO) disease severity scale at the time of sample collection, taking into account activity level, ventilatory requirement, end-organ failure including need for vasopressors and extracorporeal membrane oxygenation, and death to reflect COVID-19 disease severity 27 . If a patient did not experience the primary outcome, it was treated as a censored event and censoring time was assigned as 60 days. Kolmogorov-type supremum tests were used to evaluate proportional hazards assumptions for all models. To evaluate the discriminatory ability of the biomarkers, the C-index was estimated for individual biomarkers, using the all available urinary biomarkers per patient 28 .

As a supplementary analysis, we compared biomarker levels of urinary albumin, KIM-1, IL-18, UMOD, EGF, MCP-1, NGAL, and YKL-40 in our patient population with post-operative biomarker levels in patients with cardiac surgery-associated AKI from the Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) Study 20 , in brain-dead donors at the time of nephrectomy for organ retrieval for kidney transplantation in the Deceased Donor Study (DDS) 29 , and marathon runners with exercise stress-associated AKI to demonstrate the degree of injury or inflammation in patients with COVID-19 in comparison to other clinical settings 30 . Specifically, for this analysis, we used biomarker measurements in any patient with KDIGO Stage 1 or greater AKI across all comparison groups. We used preoperative biomarker levels from urine samples of patients in the TRIBE-AKI Study prior to cardiac surgery as the reference 31 . These measurements were chosen specifically because while J o u r n a l P r e -p r o o f not all of these patients were fully healthy, pre-operative urine samples were collected at the time of anesthesia clearance before the clear insult leading to AKI in this population. The other cohorts (post-cardiac surgery, exercise stress, brain death) were chosen to highlight different clinical scenarios both inpatient and outpatient where biomarkers have been applied previously.

For exercise stress-associated AKI, blood and urine biomarkers of injury and inflammation were measured from biosamples obtained within 30 minutes of completing a marathon in 23

individuals, compared to pre-race values 30 . Further details are provided in the Items S1.

All analyses were performed in SAS (version 9.4; SAS Institute, Cary, North Carolina) and R (version 3.1.2; R Foundation for Statistical Computing, Vienna, Austria). All tests of statistical significance were 2-sided, with P < .05 considered significant. IRB approval was obtained for all patient samples as part of this study, either with consent for prospective urine sample collection or through waiver of consent for leftover clinical samples.

A total of 178 patients had urine samples collected during their hospital admission.

Twenty-two patients who did not have urine samples obtained before the onset of the primary outcome were excluded. We also excluded 3 additional patients who had baseline serum creatinine above 4 mg/dL, resulting in a final analytic population of 153 patients with a total of 218 samples (Figure S1 ). Urine samples were available at a median of 6 (IQR: 2-10) days after hospital admission. Table 1 The median length of COVID-19 hospitalization in this study was 11 (IQR 6-25) days. In total, 24 (16%) patients developed the primary outcome. Of these patients, 14 developed stage 3 AKI, 7 required dialysis, and 19 died during the study period ( Table 1) . The primary outcome occurred at a median of 25 (IQR 15-30) days after hospital admission ( Figure S2 ). Prior to first biomarker measurement, a total of 48 (31%) patients received some form of steroid therapy (dexamethasone, hydrocortisone, or methylprednisolone), 57 (37%) patients received tocilizumab, 24 (16%) received remdesivir, and 58 (38%) received hydroxychloroquine. 

We assessed the ability of a select number of individual biomarkers and combinations of biomarkers to discriminate for the primary outcome, using all available biomarker measurements ( Table 2) . Urinary albumin yielded a C-index of 0.62, whereas urinary NGAL and EGF yielded C-indexes of 0.80 and 0.75, respectively. Combinations of 2 biomarkers improved discrimination; the C-indexes for the combination of urinary EGF and NGAL and for the combination of EGF and MCP-1 were 0.84 and 0.85 respectively. The findings were similar for non-indexed or urinary biomarkers indexed to urinary creatinine.

We performed additional analysis looking at an expanded composite outcome of stage 2 or 3 AKI, dialysis, or death up to 60 days of hospital admission. Because we excluded patients who had a biomarker measurement after the outcome occurred, our new analytic population for this analysis was 140 patients, of whom 26 (19%) developed the composite outcome. We (Table S4) .

Additional analysis on the association of biomarkers with stage 2/3 AKI or dialysis, excluding death, yielded largely similar results.

We used pre-operative urinary biomarker levels in patients from the TRIBE-AKI Study as a reference group in our comparisons of biomarker levels across cohorts. Nearly 100% of patients with COVID-19 associated AKI, regardless of stage, had urinary IL-18 and MCP-1 levels above the 90 th percentile of reference values (Figure 2) . Similarly, over 50% of patients with COVID-19 associated AKI had urinary NGAL levels above the 90 th percentile of reference values. In general, the degree of kidney injury based on biomarker levels above the reference pre-operative level was generally similar in COVID-19-associated AKI compared with other AKI settings. Markers of injury and inflammation, namely IL-18 and MCP-1, were relatively more elevated than markers of glomerular injury (albumin) or tubular health (UMOD) in the setting of COVID-19. In general, the relative degree of kidney injury in those with COVID-19associated AKI by NGAL or KIM-1 level was slightly higher than in those with exercise-stress induced AKI.

Compared with pre-operative cardiac surgery patients, patients with COVID-19 who did not develop clinical AKI had higher levels of injury and inflammatory biomarkers, suggesting the presence of subclinical AKI (Figure 3) . Within each cohort, roughly 30%-40% of patients had urinary NGAL levels above the 90 th percentile of reference values, and between 60% and 65% of each cohort had IL-18 levels above the 90 th percentile of reference values.

In this prospective study of patients hospitalized with COVID-19, we demonstrated that urinary biomarkers of injury, inflammation, and repair were associated with adverse kidney outcomes up to 60 days. We identified significant associations between urinary NGAL, KIM-1, MCP-1, and EGF with the primary outcome. The discriminatory ability of the individual biomarkers EGF, NGAL, and MCP-1 alone was higher than that of urinary albumin alone and improved in pairwise combinations of these 3 biomarkers. Neither urine microscopy score nor the presence of viral RNA in the urine of patients with COVID-19 were associated with the primary outcome. We also demonstrated that the degree of kidney injury by biomarker level was similar in COVID-19-associated AKI compared with AKI in other clinical settings, and that a substantial proportion of patients had evidence of subclinical AKI (abnormal urinary biomarkers but no change in kidney function).

The associations of urinary biomarkers with stage 3 AKI, dialysis, and death are consistent with previous studies from our group and others 15, 32, 33 , and may reflect the kidney's response to injury and inflammation due to COVID-19. Moreover, our study findings may localize kidney injury in COVID-19 to specific segments of the nephron, particularly within the renal tubule. Based on the significant association between higher levels of urinary NGAL and the primary outcome, patients with COVID-19 may be at increased risk for either proximal or distal tubular injury, as NGAL serves as a marker of global tubular injury that is rapidly upregulated in the setting of ischemia and tubular stress [34] [35] [36] .

Patients who developed stage 3 AKI, dialysis, or death had relatively higher levels of KIM-1, primarily associated with proximal tubular injury, and IL-18, strongly associated with proximal tubular inflammation 38 48 . EGF is a growth factor that serves as a marker for repair after either muscle and kidney tissue injury 49 . Urinary EGF levels correlate well with creatinine clearance 50 , and lower urinary EGF levels have been associated with AKI 50 . Therefore, we provide evidence that both proximal and distal tubular damage may be occurring. Our analysis of inflammatory markers, including urinary TNF-α and IL-6, and their significant associations with the primary outcome corroborates the global systemic inflammatory response to SARS-CoV-2 leads to significant end-organ injury 51, 52 .

Inflammatory marker elevations much higher than reference values confirm findings in prior studies 51 , and also indicate that the inflammation in COVID-19-associated AKI is significant even at stage 1 and 2 and comparable to other clinical settings. Furthermore, we demonstrated that even among patients with COVID-19 who did not develop clinical AKI based on serum creatinine, biomarkers were significantly elevated above reference values, similar to patients following cardiac surgery 20,53 . Given the clear associations between subclinical AKI and J o u r n a l P r e -p r o o f long-term outcomes in other settings, the subset of patients with subclinical kidney injury may represent a very high-risk group that will require close follow-up of renal function upon discharge 17 .

Our study also has some limitations. We did not have consistent data on daily or hourly urine output trends in these patients, and thus we defined AKI only using serum creatinine criteria. We measured several biomarkers as we wanted to identify candidates can be validated in future studies. Thus there is a risk of type 1 error from multiple comparisons but all of the primary biomarkers have shown association with other AKI studies. To limit chance findings from multiple comparisons, we selected biomarkers with high pre-test probability based on our experience with other AKI settings. Although our primary composite outcome included death up to 60 days from admission, deaths that occurred after hospital discharge but within the 60-day window may have been incompletely captured. Also, there was significant heterogeneity in the timing of urine processing. However, the majority of biomarkers that were significant are robust to handling procedures such as lack of centrifugation and being left at 4 °C or room temperature for up to 48 hours (Table S5) 54 . Furthermore, the relatively few events limited our ability to adjust for potential confounders in our analyses. However, the discriminatory potential of these biomarkers for severe events suggests that these biomarkers can be used by themselves or in combination to predict future events. However, the interpretation of C-indices in this study is somewhat limited given the small cohort size, and along with the lack of a validation cohort there is a risk for overfitting.

Our study offers a number of strengths with important clinical implications for the care of patients with COVID-19. We were able to obtain urine samples from 2 different study sites with different demographic characteristics, allowing for a more diverse patient population and more J o u r n a l P r e -p r o o f generalizable results. Despite the significant heterogeneity in the pre-processing of urine samples, the biomarker measurements were robust with excellent analytical precision. Our study can therefore offer insights into a pragmatic approach for the use of urinary biomarker measurements that can be implemented in clinical care.

In summary, we have shown that urinary biomarkers can help identify patients who are hospitalized with COVID-19 and at high risk for adverse kidney outcomes and death. These findings may improve risk stratification of patients admitted with COVID-19. The degree of tubular injury and inflammation does not appear to be overtly higher than in other common settings of AKI. Subclinical AKI, as defined by elevations in urinary biomarkers, was present in 30-50% of individuals who did not manifest clinical AKI. Further studies are needed to validate these findings and assess the association of the biomarkers with risk for CKD as well as the potential long-term consequences associated with subclinical AKI after COVID-19. 48 (31%) a: baseline = baseline serum creatinine, within 7-365 days of hospital admission b: AKI = acute kidney injury c: steroid = any administration of dexamethasone, methylprednisolone, or hydrocortisone d: Urine microscopy score based on number of renal tubular epithelial cells per high-power field, and number of granular casts per low-power field. Urine microscopy was completed in 59 participants (9 with the primary outcome). Heatmap showing the percentage of patients who have AKI in the setting of COVID-19, following cardiac surgery (TRIBE-AKI cohort), following brain death (DDS cohort), and in the setting of exercise stress (marathon-associated AKI). For exercise stress-associated AKI, blood and urine biomarkers were measured from biosamples obtained within 30 minutes of completing a marathon. Further The colors denote the percentage of patients by AKI stage who have biomarker levels above the 90 th percentile of reference value, based on cardiac surgery preoperative values. Among patients with COVID-19-associated AKI, 40% of patients with stage 1 AKI had KIM-1 levels above the 90 th percentile of reference, while 50% of patients with stage 2 AKI had KIM-1 levels above the 90 th percentile of reference, and 60% of patients with stage 3 AKI had KIM-1 levels above the 90 th percentile of reference. Similarly, among kidney donors following brain death, 70% of patient with stage 1 AKI had MCP-1 levels above the 90 th percentile of reference, while 80% of patients with stage 2 AKI had MCP-1 levels above the 90 th percentile of reference, and 90% of patients with stage 3 AKI had MCP-1 levels above the 90 th percentile of reference. *Sample size by AKI stage: -COVID-19: stage 1, n = 56; stage 2, n = 31; stage 3, n = 20 -Cardiac surgery: stage 1, n = 456; stage 2, n = 34; stage 3, n = 31 -Brain death: stage 1, n = 275; stage 2, n = 93; stage 3, n = 76 -Exercise stress: stage 1, n = 9; stage 2, n = 2 

Clinical Characteristics of Coronavirus Disease 2019 in China

Johns Hopkins global coronavirus 2019 map

Baseline Characteristics and Outcomes of 1591

Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

AKI in Hospitalized Patients with COVID-19

Acute kidney injury in patients hospitalized with COVID-19

The Association of COVID-19 With

Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study

Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19

AKI in Hospitalized Patients with and without COVID-19: A Comparison Study

COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup

Long-term Health Consequences of COVID-19

Serum Creatinine: Not So Simple! Nephron

Urine TNF-alpha and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight

Urinary biomarkers and progression of AKI in patients with cirrhosis

Subclinical AKI--an emerging syndrome with important consequences

Patient Trajectories Among Persons Hospitalized for COVID-19

Urinary biomarkers of AKI and mortality 3 years after cardiac surgery

Neutrophil gelatinaseassociated lipocalin as a marker of postoperative acute kidney injury following cardiac surgery in patients with pre-operative kidney impairment

Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int

Comparison of the performance of the IDEXX SediVue Dx® with manual microscopy for the detection of cells and 2 crystal types in canine and feline urine

A Tutorial on Evaluating the Time-Varying Discrimination Accuracy of Survival Models Used in Dynamic Decision Making

Associations between Deceased-Donor Urine Injury Biomarkers and Kidney Transplant Outcomes

Kidney Injury and Repair Biomarkers in Marathon Runners

Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery

Urinary Biomarkers at the Time of AKI Diagnosis as Predictors of Progression of AKI among Patients with Acute Cardiorenal Syndrome

Urine YKL-40 is associated with progressive acute kidney injury or death in hospitalized patients

Biomarkers of Acute and Chronic Kidney Disease

The Ngal reporter mouse detects the response of the kidney to injury in real time

Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons

Osteopontin predicts survival in critically ill patients with acute kidney injury

Urinary interleukin-18 is a marker of human acute tubular necrosis

SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule

Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment

MCP-1 gene activation marks acute kidney injury

Plasma Monocyte Chemotactic Protein-1 Is Associated With Acute Kidney Injury and Death After Cardiac Operations

Urinary EGF and MCP-1 and risk of CKD after cardiac surgery. JCI Insight

The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy

Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease

Expression of epidermal growth factor and its receptor in normal and diseased human kidney: An immunohistochemical and in situ hybridization study

Potential physiologic roles for epidermal growth factor in the kidney

Urinary epidermal growth factor levels in patients with acute renal failure

The trinity of COVID-19: immunity, inflammation and intervention

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Results from the TRIBE-AKI Study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery

Sample Processing and Stability for Urine Biomarker Studies